<DOC>
	<DOCNO>NCT00572130</DOCNO>
	<brief_summary>Rexin-G tumor-targeted gene medicine design seek destroy primary tumor metastatic cancer without side effect standard chemotherapy . The objective study : ( 1 ) evaluate clinical effectiveness intravenous injection Rexin-G , tumor-targeted gene vector , control tumor growth prolong life , ( 2 ) evaluate over-all safety .</brief_summary>
	<brief_title>Phase II Study Intravenous Rexin-G Osteosarcoma</brief_title>
	<detailed_description>The adaptive trial design advance Phase II study incorporates ( ) dose schedule base patient 's estimate tumor burden standard dose per kilogram body weight body surface area , ( 2 ) tumor response evaluation process unique manner osteosarcoma respond favorably therapy , i.e. , necrosis increase calcification metastatic tumor decrease glucose utilization use PET-CT imaging study . Twenty thirty patient receive Rexin-G either Dose Level 1 2 . Patients assign dose level base estimate tumor burden measure PET-CT image study . Estimated tumor burden measure multiply sum long diameter target lesion cm 10e9 cancer cell . If tumor burden le 10 billion cell , patient assign Dose Level 1 , tumor burden great 10 billion cell , patient assign Dose Level 2 . *Treatment Cycle Dose Level Vector Dose/Day Max.Volume/Dose Two time week 1 1.0 x 10e11 cfu 200 ml Three time week 2 1.0 x 10e11 cfu 200 ml * Each treatment cycle six week ( four week treatment two week rest ) . Patients resolution toxicity &lt; grade I may repeat cycle . After one treatment cycle , principal investigator may recommend surgical debulking complete surgical removal . If residual disease present either histopathological examination PET-CT scan , repeat treatment cycle may give 3-4 week surgery , surgical incision heal , patient &lt; grade I toxicity .</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<criteria>1 . Patient recurrent metastatic osteosarcoma consider refractory know therapy . 2 . Histologically cytologically confirm osteosarcoma measurable . 3 . Adequate hepatic function : Total bilirubin &lt; 2.0 mg/dL ( upper limit include ) ; AST/ALT &lt; 2x institutional norm ; alkaline phosphatase &lt; 2.5x upper limit institutional norm unless patient extensive bone metastasis . Patients elevate alkaline phosphatase due extensive liver disease exclude study ; albumin &gt; 3.0 mg/dL . There must substantial ascites . PT PTT must within normal limit . 4 . Performance status must &lt; 1 ( ECOG 01 ) life expectancy least 3 month . 5 . Hemoglobin &gt; 9 gm % 6 . Absolute granulocyte count &gt; 1000/uL , platelet count &gt; 100,000/uL . 7 . Serum creatinine le 1.5 mg % . 8 . There must plan patient receive cancer therapy date enrollment completion 6week followup visit . 9 . Accessibility peripheral central IV line 10 . Age &gt; 10 year 11 . Patients chemotherapy minimum 4 week prior initiation therapy recover Grade 1 less toxicity . 12 . The ability understand willingness sign write informed consent document . 1 . Prior malignancy , except nonmelanoma skin cancer , stage 1 breast cancer , CIS cervix patient diseasefree 5 year . 2 . Woman pregnant nursing 3 . Fertile patient unless agree use barrier contraception ( condoms spermicide jelly ) vector infusion period six week infusion . Male patient must agree use barrier contraception . 4 . Patients transfusion dependent ( one transfusion per month ) 5 . Patients medical , psychiatric , social condition would compromise successful adherence protocol . 6 . Patient meet inclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Tumor-targeted gene medicine</keyword>
	<keyword>Cyclin G1 gene</keyword>
	<keyword>Osteosarcoma</keyword>
</DOC>